Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120

Background: Many researchers have investigated the use of Chinese herbs to delay the progression of chronic kidney disease (CKD) through their effects on colonic microflora and microbiota-derived metabolites. However, whether FuZhengHuaYuJiangZhuTongLuo (FZHY) has effects that are similar to those o...

Full description

Bibliographic Details
Main Authors: Ziwei Chen, Shaobo Wu, Li Huang, Jing Li, Xueying Li, Yu Zeng, Zejun Chen, Ming Chen
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024010181
_version_ 1827348438740631552
author Ziwei Chen
Shaobo Wu
Li Huang
Jing Li
Xueying Li
Yu Zeng
Zejun Chen
Ming Chen
author_facet Ziwei Chen
Shaobo Wu
Li Huang
Jing Li
Xueying Li
Yu Zeng
Zejun Chen
Ming Chen
author_sort Ziwei Chen
collection DOAJ
description Background: Many researchers have investigated the use of Chinese herbs to delay the progression of chronic kidney disease (CKD) through their effects on colonic microflora and microbiota-derived metabolites. However, whether FuZhengHuaYuJiangZhuTongLuo (FZHY) has effects that are similar to those of AST-120 on CKD needs to be elucidated. Methods: In this study, we compared the effects of FZHY and AST-120 on the colonic microbiota and plasma metabolites in the CKD rat model. We developed a unilateral ureteral obstruction (UUO)-induced CKD rat model and then administered FZHY and AST-120 to these model rats. Non-targeted metabolomic LC-MS analysis, 16S rRNA sequencing, and histopathological staining were performed on plasma, stool, and kidney tissues, respectively, and the joint correlation between biomarkers and metabolites of candidate bacteria was analyzed. Results: Our results showed that administering FZHY and AST-120 effectively ameliorated UUO-induced abnormal renal function and renal fibrosis and regulated the composition of microbiota and metabolites. Compared to the UUO model group, the p_Firmicutes and o_Peptostreptococcales_Tissierellales were increased, while 14 negative ion metabolites were upregulated and 21 were downregulated after FZHY treatment. Additionally, 40 positive ion metabolites were upregulated and 63 were downregulated. On the other hand, AST-120 treatment resulted in an increase in the levels of g_Prevotellaceae_NK3B31_group and f_Prevotellaceae, as well as 12 upregulated and 23 downregulated negative ion metabolites and 56 upregulated and 63 downregulated positive ion metabolites. Besides, FZHY increased the levels of candidate bacterial biomarkers that were found to be negatively correlated with some poisonous metabolites, such as 4-hydroxyretinoic acid, and positively correlated with beneficial metabolites, such as l-arginine. AST-120 increased the levels of candidate bacterial biomarkers that were negatively correlated with some toxic metabolites, such as glycoursodeoxycholic acid, 4-ethylphenol, and indole-3-acetic acid. Conclusion: FZHY and AST-120 effectively reduced kidney damage, in which, the recovery of some dysregulated bacteria and metabolites are probably involved. As their mechanisms of regulation were different, FZHY might play a complementary role to AST-120 in treating CKD.
first_indexed 2024-03-08T00:11:15Z
format Article
id doaj.art-8a85d1cde09846c9bb2384a4ad1f83cb
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-03-08T00:11:15Z
publishDate 2024-02-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-8a85d1cde09846c9bb2384a4ad1f83cb2024-02-17T06:39:13ZengElsevierHeliyon2405-84402024-02-01103e24987Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120Ziwei Chen0Shaobo Wu1Li Huang2Jing Li3Xueying Li4Yu Zeng5Zejun Chen6Ming Chen7School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Clinical Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu Traditional Chinese and Western Medicine Hospital, Chengdu First People's Hospital, Chengdu, Sichuan 610072, ChinaDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China; Corresponding author. Department of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shierqiao Street, Chengdu, Sichuan 610072, China.Background: Many researchers have investigated the use of Chinese herbs to delay the progression of chronic kidney disease (CKD) through their effects on colonic microflora and microbiota-derived metabolites. However, whether FuZhengHuaYuJiangZhuTongLuo (FZHY) has effects that are similar to those of AST-120 on CKD needs to be elucidated. Methods: In this study, we compared the effects of FZHY and AST-120 on the colonic microbiota and plasma metabolites in the CKD rat model. We developed a unilateral ureteral obstruction (UUO)-induced CKD rat model and then administered FZHY and AST-120 to these model rats. Non-targeted metabolomic LC-MS analysis, 16S rRNA sequencing, and histopathological staining were performed on plasma, stool, and kidney tissues, respectively, and the joint correlation between biomarkers and metabolites of candidate bacteria was analyzed. Results: Our results showed that administering FZHY and AST-120 effectively ameliorated UUO-induced abnormal renal function and renal fibrosis and regulated the composition of microbiota and metabolites. Compared to the UUO model group, the p_Firmicutes and o_Peptostreptococcales_Tissierellales were increased, while 14 negative ion metabolites were upregulated and 21 were downregulated after FZHY treatment. Additionally, 40 positive ion metabolites were upregulated and 63 were downregulated. On the other hand, AST-120 treatment resulted in an increase in the levels of g_Prevotellaceae_NK3B31_group and f_Prevotellaceae, as well as 12 upregulated and 23 downregulated negative ion metabolites and 56 upregulated and 63 downregulated positive ion metabolites. Besides, FZHY increased the levels of candidate bacterial biomarkers that were found to be negatively correlated with some poisonous metabolites, such as 4-hydroxyretinoic acid, and positively correlated with beneficial metabolites, such as l-arginine. AST-120 increased the levels of candidate bacterial biomarkers that were negatively correlated with some toxic metabolites, such as glycoursodeoxycholic acid, 4-ethylphenol, and indole-3-acetic acid. Conclusion: FZHY and AST-120 effectively reduced kidney damage, in which, the recovery of some dysregulated bacteria and metabolites are probably involved. As their mechanisms of regulation were different, FZHY might play a complementary role to AST-120 in treating CKD.http://www.sciencedirect.com/science/article/pii/S2405844024010181FuZhengHuaYuJiangZhuTongLuo recipeAST-12016S rRNA sequencingGut microbiotaMetabolism
spellingShingle Ziwei Chen
Shaobo Wu
Li Huang
Jing Li
Xueying Li
Yu Zeng
Zejun Chen
Ming Chen
Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
Heliyon
FuZhengHuaYuJiangZhuTongLuo recipe
AST-120
16S rRNA sequencing
Gut microbiota
Metabolism
title Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
title_full Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
title_fullStr Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
title_full_unstemmed Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
title_short Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120
title_sort colonic microflora and plasma metabolite based comparative analysis of unilateral ureteral obstruction induced chronic kidney disease after treatment with the chinese medicine fuzhenghuayujiangzhutongluo and ast 120
topic FuZhengHuaYuJiangZhuTongLuo recipe
AST-120
16S rRNA sequencing
Gut microbiota
Metabolism
url http://www.sciencedirect.com/science/article/pii/S2405844024010181
work_keys_str_mv AT ziweichen colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT shaobowu colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT lihuang colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT jingli colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT xueyingli colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT yuzeng colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT zejunchen colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120
AT mingchen colonicmicrofloraandplasmametabolitebasedcomparativeanalysisofunilateralureteralobstructioninducedchronickidneydiseaseaftertreatmentwiththechinesemedicinefuzhenghuayujiangzhutongluoandast120